Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia

Endocrine Pathology

Volumn 25, Issue 4, 2014, Pages 371-377

  Righi, Luisella ^a   Volante, Marco ^a   Rapa, Ida ^a   Vatrano, Simona ^a   Pelosi, Giuseppe ^b   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Carcinoid; Lung; mTOR; Neuroendocrine tumor; Predictive marker; Somatostatin receptor

Indexed keywords

BUB1 RELATED PROTEIN; CYCLIN DEPENDENT KINASE 1; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN RET; PROTEIN SSTR2A; SCATTER FACTOR RECEPTOR; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; STEM CELL FACTOR; SURVIVIN; THYMIDYLATE SYNTHASE; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR PAX5; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; MTOR PROTEIN, HUMAN; SOMATOSTATIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; ATYPICAL CARCINOID; BENIGN TUMOR; BIRC5 GEEN; BUB1 GENE; C MET GENE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CD44 GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IL20RA GENE; IMMUNOPHENOTYPING; KLK12 GENE; LARGE CELL CARCINOMA; LUNG NEUROENDOCRINE NEOPLASIA; LUNG TUMOR; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; ONCOGENE; OTP GENE; PREDICTION; PROTEIN EXPRESSION; PROTEIN TARGETING; RET GENE; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SURVIVIN GENE; TYPICAL CARCINOID; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CARCINOID TUMOR; CYTOCHEMISTRY; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE;

CARCINOID TUMOR; HISTOCYTOCHEMISTRY; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84911806523     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-014-9335-6     Document Type: Article

References (58)

1. Oberg K, Hellman P, Ferolla P, Papotti M Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii120-123, 2012.
2. Noel-Savina E, Descourt R Focus on treatment of lung carcinoid tumor. Onco Targets Ther 6: 1533–1537, 2013.
3. Moran CA, Suster S, Coppola D, Wick MR Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 131: 206–221, 2009.
4. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: Tumours of the Lung, Pleura, Thymus and Heart, Lyon: IARC Press, 2004.
5. Travis WD, Giroux DJ, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 3: 1213–1223, 2008.
6. Sobin LH: TNM classification of malignant tumors, Oxford, 2009.
7. Travis WD Advances in neuroendocrine lung tumors. Ann Oncol 21 Suppl 7: vii65-71, 2010
8. Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba, II, Moran CA Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71: 34–41, 2011.
9. Arrigoni MG, Woolner LB, Bernatz PE Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 64: 413–421, 1972.
10. Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934–944, 1998.
11. Travis WD, Linnoila RI, Tsokos MG et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15: 529–553, 1991.
12. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91: 1992–2000, 2001.
13. Sturm N, Rossi G, Lantuejoul S et al. 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology 42: 156–166, 2003.
14. Pelosi G, Rossi G, Cavazza A et al. DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol 21: 229–239, 2013.
15. Jiang SX, Kameya T, Asamura H et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 17: 222–229, 2004.
16. Rekhtman N Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134: 1628–1638, 2010.
17. La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457: 497–507, 2010.
18. Tsuta K, Liu DC, Kalhor N, Wistuba, II, Moran CA Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 136: 252–259, 2011.
19. Bosman F: Tumours of the Digestive Tract, Lyon: IARC Press, 2010.
20. Walts AE, Ines D, Marchevsky AM Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol 25: 1258–1264, 2012.
21. Pelosi G, Rindi G, Travis WD, Papotti M Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 9: 273–284, 2014.
22. Pelosi G, Rodriguez J, Viale G, Rosai J Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 29: 179–187, 2005.
23. Asamura H, Kameya T, Matsuno Y et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24: 70–76, 2006.
24. Costes V, Marty-Ane C, Picot MC et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 26: 740–745, 1995.
25. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5: 453–459, 2010.
26. Grimaldi F, Muser D, Beltrami CA et al. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. Front Endocrinol (Lausanne) 2: 20, 2011.
27. Rindi G, Klersy C, Inzani F et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 21: 1–16, 2014.
28. Travis WD Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 25 Suppl 1: S18-30, 2012.
29. Pelosi G, Papotti M, Rindi G, Scarpa A Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocrine Pathology, 2014.
30. Swarts DR, Claessen SM, Jonkers YM et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol 179: 1129–1137, 2011.
31. Beasley MB, Lantuejoul S, Abbondanzo S et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 34: 136–142, 2003.
32. Swarts DR, Ramaekers FC, Speel EJ Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 1826: 255–271, 2012.
33. Debelenko LV, Swalwell JI, Kelley MJ et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 28: 58–65, 2000.
34. Swarts DR, Scarpa A, Corbo V et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. J Clin Endocrinol Metab 99: E374–378, 2014.
35. Fernandez-Cuesta L, Peifer M, Lu X et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 5: 3518, 2014.
36. Tanca A, Addis MF, Pagnozzi D et al. Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives. J Proteomics 74: 359–370, 2011.
37. Swarts DR, Henfling ME, Van Neste L et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res 19: 2197–2207, 2013.
38. Swarts DR, Van Neste L, Henfling ME et al. An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis 34: 2726–2737, 2013.
39. Rudin CM, Durinck S, Stawiski EW et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44: 1111–1116, 2012.
40. Nakamura H, Tsuta K, Yoshida A et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol 66: 705–707, 2013.
41. Odate S, Nakamura K, Onishi H et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer 79: 205–214, 2013.
42. Ceppi P, Volante M, Ferrero A et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14: 1059–1064, 2008.
43. Tsuta K, Wistuba, II, Moran CA Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung. Pathol Res Pract 208: 470–474, 2012.
44. Righi L, Volante M, Tavaglione V et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 21: 548–555, 2010.
45. Ali G, Boldrini L, Capodanno A et al. Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med 2: 787–792, 2011.
46. Righi L, Volante M, Rapa I et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17: 977–987, 2010.
47. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005–2012, 2011.
48. Gagliano T, Bellio M, Gentilin E et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer 20: 463–475, 2013.
49. Bago-Horvath Z, Sieghart W, Grusch M et al. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology 96: 228–237, 2012.
50. Rossi G, Cavazza A, Marchioni A et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23: 8774–8785, 2005.
51. Iyoda A, Travis WD, Sarkaria IS et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med 2: 1041–1045, 2011.
52. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med 134: 1702–1705, 2010.
53. Voortman J, Harada T, Chang RP et al. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des 19: 833–840, 2013.
54. Volante M, Brizzi MP, Faggiano A et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20: 1172–1182, 2007.
55. Miederer M, Seidl S, Buck A et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36: 48–52, 2009.
56. Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15: 338–345, 2009.
57. Sodja E, Knez L, Kern I, Ovcaricek T, Sadikov A, Cufer T Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 48: 3378–3385, 2012.
58. Ceppi P, Longo M, Volante M et al. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 3: 583–589, 2008.